AngioDynamics shares plummeted on Thursday, after the company released its latest guidance for the full-year.
The medical devices maker announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million conditional upon Eximo meeting its technical and revenue milestones.
Following the acquisition, AngioDynamics now expects earnings for fiscal 2020 to range between 10 cents and 15 cents a share – a range lower than analysts’ expectation of 26 cents.
Angio CEO Jim Clemmer indicated that the acquisition of Eximo would usher in a remarkable, foundational technology for its portfolio in a way that transforms the way caregivers provide treatment to patients with PAD. "The market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices," Clemmer said.
Separately, the company reported first-quarter earnings of 8 cents a share, which is higher than analysts’ estimate of 4 cents. Its revenue of $66 million, however, came in slightly below the $67.52 million that analysts were expecting.
The Aroon Indicator for ANGO entered a downward trend on July 17, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 153 similar instances where the Aroon Indicator formed such a pattern. In of the 153 cases the stock moved lower. This puts the odds of a downward move at .
ANGO moved below its 50-day moving average on July 01, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on July 03, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.579) is normal, around the industry mean (24.469). P/E Ratio (44.843) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.705) is also within normal values, averaging (42.883).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry MedicalSpecialties